An observational study in Snake Envenomation, sponsored by BTG International Inc.. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2022-06-28.
Sponsored by BTG International Inc. · Observational
Retrospective observational review of severe envenomation treatment with CroFab
The objective of this study is to use previously collected retrospective observational data to compare treatment and outcome in patients treated with CroFab who have a severe envenomation to those with a mild/moderate envenomation.
All patients bitten by a pit viper and treated with CroFab between January 1, 2002 and December 31 2004.
The record must contain all of the following:
To be included in the Efficacy Evaluable Population (EEP) in the current analysis, each record must meet the following criteria:
Exclusion Criteria:
Patients with a calculated severity score of 5 or 6 were included in this group.
Severity Score less than 5
Severity score: in order to assess response to therapy, severity scores were calculated and compared across all recorded time points.
Time frame: at baseline and following treatment with CroFab
The presence of venom effects, comparison of venom effects over time, initial control of venom effects, recurrence of venom effects, and delayed onset of venom effects.
Time frame: following treatment
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
BTG International Inc.